Brain atrophy in seizure-free temporal lobe epilepsy: Implications for predicting pharmacoresistance

Simon S Keller^{1

2

3}

Affiliations

¹ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. simon.keller@liverpool.ac.uk.
² Department of Neuroradiology, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom. simon.keller@liverpool.ac.uk.
³ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. simon.keller@liverpool.ac.uk.

Comment

Simon S Keller. Epilepsia. 2016 May.

. 2016 May;57(5):855-6.

doi: 10.1111/epi.13364.

Simon S Keller^{1

2

3}

¹ Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom. simon.keller@liverpool.ac.uk.
² Department of Neuroradiology, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom. simon.keller@liverpool.ac.uk.
³ Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom. simon.keller@liverpool.ac.uk.

No abstract available

Comment in

In response: Brain atrophy in seizure-free temporal lobe epilepsy: Implications for predicting pharmacoresistance.
Alvim MK, Coan AC, Yasuda CL, Morita ME, Cendes F. Alvim MK, et al. Epilepsia. 2016 May;57(5):856-7. doi: 10.1111/epi.13379. Epilepsia. 2016. PMID: 27160803 No abstract available.

Progression of gray matter atrophy in seizure-free patients with temporal lobe epilepsy.
Alvim MK, Coan AC, Campos BM, Yasuda CL, Oliveira MC, Morita ME, Cendes F. Alvim MK, et al. Epilepsia. 2016 Apr;57(4):621-9. doi: 10.1111/epi.13334. Epub 2016 Feb 11. Epilepsia. 2016. PMID: 26865066